{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:25:15Z","timestamp":1768440315791,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ijantimicag.2016.02.006","type":"journal-article","created":{"date-parts":[[2016,3,20]],"date-time":"2016-03-20T00:31:05Z","timestamp":1458433865000},"page":"357-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin"],"prefix":"10.1016","volume":"47","author":[{"given":"Chantelle","family":"Browne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noemi","family":"Muszbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian M.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Andrew","family":"Seaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 6","key":"10.1016\/j.ijantimicag.2016.02.006_bib0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1469-0691.2009.03056.x","article-title":"Maximizing positive outcomes for patients with staphylococcal infections","volume":"15","author":"Stahl","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0135","series-title":"Healthcare-associated infection and antimicrobial resistance: 2010\u20132011","author":"Health Protection Agency","year":"2012"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0140","series-title":"Annual report of the European antimicrobial resistance surveillance network (EARS-Net). Antimicrobial resistance surveillance in Europe 2011","author":"European Centre for Disease Prevention Control","year":"2012"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0145","series-title":"Surveillance of surgical site infections in NHS hospitals in England, 2010\/2011","author":"Health Protection Agency","year":"2011"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0150","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1186\/2047-783X-15-12-571","article-title":"Multiresistant bacteria and current therapy \u2013 the economical side of the story","volume":"15","author":"Wilke","year":"2010","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/dkr450","article-title":"Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy","volume":"67","author":"Gould","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MAJ.0b013e3181e99aa4","article-title":"Treatment of infections caused by antimicrobial-resistant Gram-positive bacteria","volume":"340","author":"Kinney","year":"2010","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0165","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jac\/dkn329","article-title":"Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"62","author":"Lodise","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0170","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijantimicag.2010.10.029","article-title":"Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004\u20132009","volume":"37","author":"Hawser","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0175","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1128\/AAC.35.11.2282","article-title":"Daptomycin disrupts membrane potential in growing Staphylococcus aureus","volume":"35","author":"Alborn","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0180","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/cid\/cit112","article-title":"Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1mg\/L: a matched cohort study","volume":"56","author":"Murray","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0185","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2013.01.019","article-title":"Daptomycin for outpatient parenteral antibiotic therapy: a European registry experience","volume":"41","author":"Seaton","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0190","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/jac\/dkp051","article-title":"Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy","volume":"63","author":"Rehm","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0195","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/jac\/dkp135","article-title":"European Surveillance of Antimicrobial Consumption (ESAC): outpatient parenteral antibiotic treatment in Europe","volume":"64","author":"Coenen","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/postgradmedj-2011-130355","article-title":"Outpatient parenteral antibiotic therapy for infective endocarditis: a review of 4 years\u2019 experience at a UK centre","volume":"88","author":"Partridge","year":"2012","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0205","series-title":"Physician survey","year":"2012"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0210","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/02770903.2013.862543","article-title":"The influence of hospitalizations due to exacerbations or spontaneous pneumothoraxes on the quality of life, mental function and symptoms of depression and anxiety in patients with COPD or asthma","volume":"51","author":"Filipowski","year":"2013","journal-title":"J Asthma"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0215","series-title":"Nutritional and environmental medicine laboratory guide. Number 8.4","author":"BioLab Medical Unit","year":"2007"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0220","unstructured":"Department of Health. NHS reference costs. https:\/\/www.gov.uk\/government\/collections\/nhs-reference-costs [accessed December 2008]."},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0225","series-title":"Mullhaven Medical Laboratory","year":"2008"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0230","unstructured":"British National Formulary (BNF) 56. http:\/\/www.bnf.org\/bnf [accessed 01.12.08]."},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0235","series-title":"Prevention and control of healthcare associated infections","author":"National Institute for Health Care Excellence","year":"2011"},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0240","unstructured":"Personal Social Services Research Unit. Unit costs of health and social care 2011. http:\/\/www.pssru.ac.uk\/ [accessed October 2012]."},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0245","unstructured":"Department of Health. Health service cost index, Hospital and Community Health Service (HCHS) specific price inflation. http:\/\/www.pssru.ac.uk\/pdf\/uc\/uc2010\/uc2010_inflationindices.pdf [accessed 14.03.16]."},{"key":"10.1016\/j.ijantimicag.2016.02.006_bib0250","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916300218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857916300218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T06:24:11Z","timestamp":1536906251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857916300218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0924857916300218"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.02.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative healthcare-associated costs of methicillin-resistant Staphylococcus aureus bacteraemia-infective endocarditis treated with either daptomycin or vancomycin","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}